08:00 , Feb 4, 2013 |  BioCentury  |  Emerging Company Profile

Incanthera: Using, not targeting, MMP

Incanthera Ltd. has found a new use for a class of enzymes that are up-regulated in tumors and contribute to cancer progression. Rather than design inhibitors of matrix metalloproteinases, the biotech is instead using them...
08:00 , Mar 15, 2004 |  BioCentury  |  Strategy

Fitting in with AstraZeneca

Fitting in with AstraZeneca Compound Status Target/MOA Alzheimer's disease AZD0328 Preclin Nicotinic acetylcholine receptor alpha 7 agonist AZD2858 Preclin NA AZD3102 Preclin NA Astex deal Disc Small molecule inhibitor against AZN target Oncology...